<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>389</serviceExecutionTime><Drug id="64613"><DrugName>NV-556</DrugName><DrugSynonyms><Name><Value>cyclophilin inhibitors (oral, HCV, HBV, HIV), Biotica</Value></Name><Name><Value>nPT-CyP series (viral infections), Biotica</Value></Name><Name><Value>sangamide derivatives, NeuroVive</Value></Name><Name><Value>BC-556</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NVP-018</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cyclophilin inhibitors, NeuroVive Pharmaceutical/ Isomerase Therapeutics</Value></Name><Name><Value>OCB-030</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>sanglifehrin derivatives (oral, HCV/HBV), NeuroVive/Isomerase/OnCore</Value></Name><Name><Value>sanglifehrin (oral, HCV/HBV), Isomerase/Tekmira</Value></Name><Name><Value>sanglifehrin derivatives (oral, HCV/HBV), Isomerase/Tekmira/Roivant</Value></Name><Name><Value>sanglifehrin derivatives (oral, NASH/mitochondrial myopathy/hepatocellular carcinoma), NeuroVive Pharmaceutical</Value></Name><Name><Value>NV-556</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25432">Biotica Technology Ltd</CompanyOriginator><CompaniesPrimary><Company id="1050613">NeuroVive Pharmaceutical AB</Company></CompaniesPrimary><CompaniesSecondary><Company id="1032153">Arbutus Biopharma Corp</Company><Company id="1084963">Isomerase Therapeutics Ltd</Company><Company id="1100124">OnCore Biopharma Inc</Company><Company id="1104160">Roivant Sciences Ltd</Company><Company id="21110">Karolinska Institutet</Company><Company id="25432">Biotica Technology Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="64613" type="Drug"><TargetEntity id="770490" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1032153" type="Company"><TargetEntity id="4295861697" type="organizationId">Arbutus Biopharma Corp (Pre-Merger)</TargetEntity></SourceEntity><SourceEntity id="1050613" type="Company"><TargetEntity id="4298051839" type="organizationId">NeuroVive Pharmaceutical AB</TargetEntity></SourceEntity><SourceEntity id="1084963" type="Company"><TargetEntity id="5040043954" type="organizationId">Isomerase Therapeutics Ltd</TargetEntity></SourceEntity><SourceEntity id="1100124" type="Company"><TargetEntity id="5043464496" type="organizationId">Arbutus Biopharma Inc</TargetEntity></SourceEntity><SourceEntity id="1104160" type="Company"><TargetEntity id="5046658821" type="organizationId">Roivant Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="21110" type="Company"><TargetEntity id="5035523906" type="organizationId">Karolinska Institutet</TargetEntity></SourceEntity><SourceEntity id="25432" type="Company"><TargetEntity id="4297026734" type="organizationId">Biotica Technology Ltd</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2541" type="ciIndication"><TargetEntity id="10027710" type="MEDDRA"></TargetEntity><TargetEntity id="D017240" type="MeSH"></TargetEntity><TargetEntity id="-1089618013" type="omicsDisease"></TargetEntity><TargetEntity id="4916" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2637" type="ciIndication"><TargetEntity id="K75.81" type="ICD10"></TargetEntity><TargetEntity id="1412" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="43842" type="Action"><TargetEntity id="3091" type="Mechanism">Non-Structural Protein 5A (NS5A) (HCV) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="46322" type="Action"><TargetEntity id="3914" type="Mechanism">Cyclophilin D Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-08428" type="ciTarget"><TargetEntity id="134878836154813" type="siTarget">Peptidyl-prolyl cis-trans isomerase D</TargetEntity><TargetEntity id="-1473487539" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="2637">Non-alcoholic steatohepatitis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="152">Hepatitis B virus infection</Indication><Indication id="153">Hepatitis C virus infection</Indication><Indication id="158">HIV infection</Indication><Indication id="2541">Mitochondrial myopathy</Indication></IndicationsSecondary><ActionsPrimary><Action id="43842">Hepatitis C virus protein NS5A inhibitor</Action><Action id="46322">Peptidyl-prolyl cis-trans isomerase D inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="32411">Hepatitis B virus replication inhibitor</Action><Action id="2953">Anti-inflammatory</Action><Action id="15319">Hepatitis C virus replication inhibitor</Action><Action id="396">Immunosuppressant</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-25T11:17:04.000Z</LastModificationDate><ChangeDateLast>2019-06-25T00:00:00.000Z</ChangeDateLast><AddedDate>2009-10-14T07:53:50.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1050613" linkType="Company"&gt;Neurovive&lt;/ulink&gt; is investigating NV-556   (NVP-018; OCB-030; BC-556) the lead from a series of sanglifehrin derivatives derived from NeuroVive's class of Sangamide cyclophilin D  inhibitors, which acts with a directly antifibrotic mechanism of action,  for the potential oral treatment of non-alcoholic steatohepatitis (NASH) [&lt;ulink linkID="1437603" linkType="Reference"&gt;1437603&lt;/ulink&gt;], [&lt;ulink linkID="1634577" linkType="Reference"&gt;1634577&lt;/ulink&gt;],        [&lt;ulink linkID="1865421" linkType="Reference"&gt;1865421&lt;/ulink&gt;],   [&lt;ulink linkID="1868346" linkType="Reference"&gt;1868346&lt;/ulink&gt;], [&lt;ulink linkID="1891307" linkType="Reference"&gt;1891307&lt;/ulink&gt;], [&lt;ulink linkID="1901862" linkType="Reference"&gt;1901862&lt;/ulink&gt;], [&lt;ulink linkID="1915718" linkType="Reference"&gt;1915718&lt;/ulink&gt;], [&lt;ulink linkID="1919065" linkType="Reference"&gt;1919065&lt;/ulink&gt;], [&lt;ulink linkID="2132887" linkType="Reference"&gt;2132887&lt;/ulink&gt;]. By November 2016, the drug was in preclinical development with NeuroVive [&lt;ulink linkID="1868346" linkType="Reference"&gt;1868346&lt;/ulink&gt;]; in November 2018, this was still the case [&lt;ulink linkID="2092175" linkType="Reference"&gt;2092175&lt;/ulink&gt;].  In November 2018, preclinical data were reported [&lt;ulink linkID="2092175" linkType="Reference"&gt;2092175&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;NeuroVive was previously investigating the drug for mitochondrial myopathy in collaboration with &lt;ulink linkID="21110" linkType="Company"&gt;Karolinska Institutet&lt;/ulink&gt; [&lt;ulink linkID="1891307" linkType="Reference"&gt;1891307&lt;/ulink&gt;]. In January 2017, preclinical studies of NV-556 for mitochondrial myopathy were planned to be initiated [&lt;ulink linkID="1891307" linkType="Reference"&gt;1891307&lt;/ulink&gt;]. However by November 2018, this indication was no longer listed on the company's pipeline [&lt;ulink linkID="2167169" linkType="Reference"&gt;2167169&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1084963" linkType="Company"&gt;Isomerase Therapeutics&lt;/ulink&gt; and &lt;ulink linkID="1032153" linkType="Company"&gt;Arbutus Biopharma&lt;/ulink&gt; (formerly Tekmira Pharmaceuticals; following its merger with &lt;ulink linkID="1100124" linkType="Company"&gt;OnCore BioPharma&lt;/ulink&gt;), under license from Neurovive, were investigating  NV-556   (as NVP-018), as a once-daily oral formulation for the potential treatment of viral infections including HBV and HCV [&lt;ulink linkID="1390391" linkType="Reference"&gt;1390391&lt;/ulink&gt;], [&lt;ulink linkID="1454057" linkType="Reference"&gt;1454057&lt;/ulink&gt;], [&lt;ulink linkID="1501707" linkType="Reference"&gt;1501707&lt;/ulink&gt;], [&lt;ulink linkID="1634577" linkType="Reference"&gt;1634577&lt;/ulink&gt;], [&lt;ulink linkID="1591726" linkType="Reference"&gt;1591726&lt;/ulink&gt;], [&lt;ulink linkID="1625738" linkType="Reference"&gt;1625738&lt;/ulink&gt;], [&lt;ulink linkID="1634577" linkType="Reference"&gt;1634577&lt;/ulink&gt;]. &lt;ulink linkID="1104160" linkType="Company"&gt;Roivant&lt;/ulink&gt; in collaboration with Arbutus was also investigating the drug for the potential treatment of HBV infection [&lt;ulink linkID="1661502" linkType="Reference"&gt;1661502&lt;/ulink&gt;].    In March 2015, the program was in IND-enabling studies for HBV infection. At that time, the company expected to file IND in the US and initiate the phase I trials in 2015 [&lt;ulink linkID="1643180" linkType="Reference"&gt;1643180&lt;/ulink&gt;]; however, in October 2015, Arbutus had concluded that the data do not support further development of OCB-030 as a single agent or in combination with its other drug candidates and as a result it had discontinued the development of OCB-030 [&lt;ulink linkID="1707372" linkType="Reference"&gt;1707372&lt;/ulink&gt;]. In October 2015, Neurovive intends to find a suitable way to continue the drug development [&lt;ulink linkID="1707358" linkType="Reference"&gt;1707358&lt;/ulink&gt;]. In October 2016, Neurovive regained the rights to NVP-018 from Arbutus, following the termination of their agreement and its previous decision to discontinue the development of the drug. At that time, Neurovive was exploring various alternatives for further development of the drug       [&lt;ulink linkID="1865421" linkType="Reference"&gt;1865421&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Biotica was previously investigating the program for the potential treatment of HIV infection [&lt;ulink linkID="975678" linkType="Reference"&gt;975678&lt;/ulink&gt;]. In November 2011, BC-556 was nominated as a program lead [&lt;ulink linkID="1235019" linkType="Reference"&gt;1235019&lt;/ulink&gt;]. However, in March 2013, NeuroVive acquired Biotica's cyclophilin inhibitor portfolio following  the latter's move into administration [&lt;ulink linkID="1355970" linkType="Reference"&gt;1355970&lt;/ulink&gt;], [&lt;ulink linkID="1390391" linkType="Reference"&gt;1390391&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2018, in vivo data were presented at the 69th AASLD Liver Meeting in San Francisco, CA. In male mice administered with 0.2 mg streptozotocin at 2-day-old to disrupt pancreatic cells and nourished with high-fat diet (60% kcal fat) since 3-weeks of age, NV-556 (50 mg/kg, po) treatment for 6 weeks before the 14-week-old time point for the development of NASH significantly decreased collagen formation (p = 0.0281), but had no effect on inflammation, ballooning, steatosis, body and liver weight, and systemic cytokine production compared to control mice with NASH [&lt;ulink linkID="2092175" linkType="Reference"&gt;2092175&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2017, in vitro data shown that NV-556 had inhibitory effect on collagen production in models with liver fibrosis [&lt;ulink linkID="1984110" linkType="Reference"&gt;1984110&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, data on the activity of NV-566 on fibrosis and HCC in  NASH mouse models were presented at the 52nd EASL International Liver Congress in Amsterdam, the Netherlands. In a C57BL/6 STAM NASH mouse model, NV-556 (100 mg/kg) significantly reduced liver fibrosis compared with vehicle control (p &amp;lt; 0.01) and, in contrast to telmisartan, had no affect on body weight, liver weight or liver triglyceride levels. NV-566 (100 mg/kg) had no effect on HCC survival compared with vehicle group; however, a significant decrease in liver weight vs vehicle (p &amp;lt; 0.05) was reported for extended dosing with NV-556 and a trend toward reduction of the number  and maximal diameter of tumors on the liver surface was observed. In a C57BL/6 methionine and choline deficient diet mouse model, NV-556 (100 mg/kg) significantly reduced  liver fibrosis (p &amp;lt; 0.001 versus vehicle) [&lt;ulink linkID="1919585" linkType="Reference"&gt;1919585&lt;/ulink&gt;], [&lt;ulink linkID="1919546" linkType="Reference"&gt;1919546&lt;/ulink&gt;], [&lt;ulink linkID="1915718" linkType="Reference"&gt;1915718&lt;/ulink&gt;], [&lt;ulink linkID="1919065" linkType="Reference"&gt;1919065&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were reported. NVP-018 prevented fibrosis development in  an experimental model of NASH  [&lt;ulink linkID="1868346" linkType="Reference"&gt;1868346&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2014, preclinical data were presented at the 49th EASL Annual Meeting in London, UK. In stable transfected HepG2 cells, NVP-018 was more potent at inhibiting HBV when compared with &lt;ulink linkID="47857" linkType="Drug"&gt;alisporivir&lt;/ulink&gt;.  NVP-018 dose-dependently blocked the interaction between IRF-9 and cyclophilin-A and it also enhanced IFN-mediated promoter activation in various cell types. In HBV transgenic mice, NVP-018 (100 mg/kg, qd, po or ip) treatment reduced HBV (average drop of 1.2 to 1.5 log over 14 days) DNA, HBsAg and HBeAG within 2 weeks [&lt;ulink linkID="1540865" linkType="Reference"&gt;1540865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 47th EASL Annual Meeting in Barcelona, Spain. In pharmacokinetic studies, blood levels of  a single 5 mg/kg dose in mice, rats and beagle dogs,  remained at a level higher than the HCV EC90 value for more than 24 h. In vivo, in CD-1 mice, the agent did not elevate bilirubin or enzyme levels. In genotype 1a, 1b and 2a HCV infection in several replicons, NVP-018 had higher inhibitory activity compared with &lt;ulink linkID="47857" linkType="Drug"&gt;alisporivir&lt;/ulink&gt;. The compound was also active against replicons resistant to other direct-acting antiviral agents  [&lt;ulink linkID="1282374" linkType="Reference"&gt;1282374&lt;/ulink&gt;], [&lt;ulink linkID="1280225" linkType="Reference"&gt;1280225&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2011, results showed NVP-018 exhibited a very high barrier to selection of viral resistance. At that time, the company believed that the compound could be suitable for the combination with other drugs in a treatment cocktail [&lt;ulink linkID="1235019" linkType="Reference"&gt;1235019&lt;/ulink&gt;]. By October 2011, the studies had demonstrated excellent drug-drug interaction profile of NVP-018 which was suitable for combination treatment with other drugs [&lt;ulink linkID="1282275" linkType="Reference"&gt;1282275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, preclinical data were published on sangamides, a new class of sanglifehrin A amide derivatives. One of the sangamide derivatives exhibited EC50 values of 125, 63, 58 and 89 nM in the Huh5.2, H77, Huh7 and JFH-1 replicon assays, respectively, was selective over human MLR (IC50 = 1450 nM) and was selected as an advanced lead for further optimization [&lt;ulink linkID="1233127" linkType="Reference"&gt;1233127&lt;/ulink&gt;], [&lt;ulink linkID="1232974" linkType="Reference"&gt;1232974&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, preclinical data were presented at the 24th International Conference on Antiviral Research in Sofia, Bulgaria. In vitro, the compounds showed potency against HIV [&lt;ulink linkID="1189306" linkType="Reference"&gt;1189306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 46th EASL meeting in Berlin, Germany. A series of sanglifehrin A analogs  which acts as anitviral  and immunosuppresant agents, potently blocked the interactions of cyclophilins  A, B, and D with HCV NS5A. These compounds showed more potent inhibition of HCV subgenomic replicon replication when compared with sanglifehrin A and cyclosporine A and were less cytostatic with improved drug-like properties. At that time, detailed profiling of selected candidates was underway [&lt;ulink linkID="1184289" linkType="Reference"&gt;1184289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2011,  additional profiling of the compounds was ongoing to identify clinical candidates [&lt;ulink linkID="1158364" linkType="Reference"&gt;1158364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, the program reached preclinical proof-of-concept for HCV.  The most active compounds had EC50 values of 40 nM, selectivity indices of 1000, improved water solubility and oral bioavailability  [&lt;ulink linkID="1087578" linkType="Reference"&gt;1087578&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2009, in vitro assays  had demonstrated that  the nPT-CyP series showed excellent activity in the replicon system with a good selectivity index   [&lt;ulink linkID="1048023" linkType="Reference"&gt;1048023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, the program was listed in lead optimization for HCV [&lt;ulink linkID="1049443" linkType="Reference"&gt;1049443&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;NVP-018 is a  sangamide derivative from a nPT-CyP series of  polyketide, sanglifehrin A-based, non-cyclosporin, cyclophilin inhibitors  [&lt;ulink linkID="1233127" linkType="Reference"&gt;1233127&lt;/ulink&gt;], [&lt;ulink linkID="1235019" linkType="Reference"&gt;1235019&lt;/ulink&gt;],  [&lt;ulink linkID="1437603" linkType="Reference"&gt;1437603&lt;/ulink&gt;],  [&lt;ulink linkID="1508795" linkType="Reference"&gt;1508795&lt;/ulink&gt;]. It is  the oral version of the lead compound, NV-556, from NeuroVive's NASH program [&lt;ulink linkID="1868346" linkType="Reference"&gt;1868346&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-11-01T00:00:00.000Z</StatusDate><Source id="1868346" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-28T00:00:00.000Z</StatusDate><Source id="1707372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-28T00:00:00.000Z</StatusDate><Source id="1707372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-28T00:00:00.000Z</StatusDate><Source id="1707372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1084963">Isomerase Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-10-28T00:00:00.000Z</StatusDate><Source id="1707372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2541">Mitochondrial myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-29T00:00:00.000Z</StatusDate><Source id="2167169" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25432">Biotica Technology Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2541">Mitochondrial myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-29T00:00:00.000Z</StatusDate><Source id="2167169" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1084963">Isomerase Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-09T00:00:00.000Z</StatusDate><Source id="1591726" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-09T00:00:00.000Z</StatusDate><Source id="1591726" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25432">Biotica Technology Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-11T00:00:00.000Z</StatusDate><Source id="1390391" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1634577" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25432">Biotica Technology Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-05-09T00:00:00.000Z</StatusDate><Source id="1189306" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25432">Biotica Technology Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-01-12T00:00:00.000Z</StatusDate><Source id="975678" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1084963">Isomerase Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-11-20T00:00:00.000Z</StatusDate><Source id="1501707" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-11-20T00:00:00.000Z</StatusDate><Source id="1501707" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-03-11T00:00:00.000Z</StatusDate><Source id="1390391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1100124">OnCore Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-09T00:00:00.000Z</StatusDate><Source id="1591741" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1100124">OnCore Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1634577" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-05T00:00:00.000Z</StatusDate><Source id="1638813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1104160">Roivant Sciences Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-05-20T00:00:00.000Z</StatusDate><Source id="1661502" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-05T00:00:00.000Z</StatusDate><Source id="1638813" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1084963">Isomerase Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-01T00:00:00.000Z</StatusDate><Source id="1454057" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1050613">NeuroVive Pharmaceutical AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2541">Mitochondrial myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-10T00:00:00.000Z</StatusDate><Source id="1891307" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2541">Mitochondrial myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-10T00:00:00.000Z</StatusDate><Source id="1891307" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-08041"><Name>Hepatitis C virus protein NS5A</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-08428"><Name>Peptidyl-prolyl cis-trans isomerase D</Name><SwissprotNumbers><Swissprot>P0ADY1</Swissprot><Swissprot>P0ADY2</Swissprot><Swissprot>P0C1I1</Swissprot><Swissprot>P26882</Swissprot><Swissprot>P44092</Swissprot><Swissprot>P53691</Swissprot><Swissprot>P57550</Swissprot><Swissprot>Q08752</Swissprot><Swissprot>Q11004</Swissprot><Swissprot>Q2U0E0</Swissprot><Swissprot>Q4HXF6</Swissprot><Swissprot>Q4P0V4</Swissprot><Swissprot>Q4WIF3</Swissprot><Swissprot>Q5ACI8</Swissprot><Swissprot>Q5B4E7</Swissprot><Swissprot>Q5KFV5</Swissprot><Swissprot>Q5U8Z7</Swissprot><Swissprot>Q6BXZ7</Swissprot><Swissprot>Q6CBP4</Swissprot><Swissprot>Q6CL78</Swissprot><Swissprot>Q6DGG0</Swissprot><Swissprot>Q6FNU6</Swissprot><Swissprot>Q75A33</Swissprot><Swissprot>Q7VKX4</Swissprot><Swissprot>Q89A98</Swissprot><Swissprot>Q8K987</Swissprot><Swissprot>Q9CR16</Swissprot><Swissprot>Q9P3X9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1032153">Arbutus Biopharma Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1050613">NeuroVive Pharmaceutical AB</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="1056760">Swedish Foundation for Strategic Research</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1084963">Isomerase Therapeutics Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1144311">Engitix Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21110">Karolinska Institutet</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25432">Biotica Technology Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="17">Patent - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]1[C@H](/C=C/C=C/C[C@H](OC(=O)[C@@H]2CCCN(N2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]([C@@H]1O)CCC(=O)C)C(C)C)Cc3cccc(c3)O)/C(=C/C=C/C(=O)N4CCCCO4)/C)O</Smiles></StructureSmiles><Deals><Deal id="144338" title="NeuroVive to acquire IP rights of Biotica's cyclophilin inhibitor and related technology assets"></Deal><Deal id="145433" title="Isomerase Therapeutics to develop and commercialize NeuroVive's cyclophilin-inhibitors     "></Deal><Deal id="150776" title="OnCore Biopharma to develop and commercialize NeuroVive's cyclophilin inhibitors for chronic HBV and HCV infection worldwide"></Deal><Deal id="236231" title="Karolinska to study NeuroVive's NV-556 for mitochondrial myopathy"></Deal><Deal id="237047" title="Engitix and NeuroVive Pharmaceutical to assess the anti-fibrotic properties of NV-556 using human liver 3D models    "></Deal><Deal id="243466" title="SFF to award NeuroVive funding to study the role of cyclophilins including NVP-024 in liver cancer "></Deal></Deals><PatentFamilies><PatentFamily id="2224998" number="WO-2011098809" title="Sanglifehrin based compounds"></PatentFamily><PatentFamily id="2519422" number="WO-2013061052" title="Novel dosage form"></PatentFamily><PatentFamily id="4060126" number="WO-2018091634" title="Use of sanglifehrin macrocyclic analogues as anticancer compounds"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbutus Biopharma Corp" id="1032153"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroVive Pharmaceutical AB" id="1050613"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Isomerase Therapeutics Ltd" id="1084963"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biotica Technology Ltd" id="25432"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>